Researchers successfully guided regenerating sensory axons to their correct targets and formed synapses, but not electrically active connections due to lack of myelin sheath. The study suggests that restoring the myelin sheath is crucial for fully restoring function in injured spinal cords.
A randomized controlled trial found that raltegravir-based combination treatment is effective and well-tolerated in treatment-naive patients, with faster action and fewer adverse events than efavirenz. The study included 281 patients given raltegravir and 282 given efavirenz.
A study has pinpointed a genetic link for increased risk of urinary bladder cancer, finding that people with a specific variant have a 30-40% higher risk. The research suggests potential for targeted prevention and early treatment efforts to save lives.
A new class of HIV antiretroviral drugs has been shown to be effective for patients beginning treatment, with raltegravir demonstrating faster action and lower side effects than efavirenz. The study found that half the raltegravir group reached viral suppression by week four, compared to less than 20% of the efavirenz group.
Research reveals that even after successful treatment with acyclovir, genital herpes sores create an environment conducive to HIV infection. The study found high concentrations of specific immune cells at the site of lesions, increasing the risk of HIV transmission.
A study by Walter and Eliza Hall Institute scientists suggests that luminal progenitor cells, the 'daughters' of breast stem cells, are likely responsible for basal-like breast tumours in women with BRCA1 mutations. The research, published in Nature Medicine, represents a major shift in understanding how breast cancer develops.
Recent studies at WCLC reveal that specific volatile organic compounds can help detect early stage lung cancer, while iloprost improves endobronchial dysplasia in former smokers. Researchers hope to develop a test examining exhaled breath for early detection of lung cancer using this information.
Researchers at Yale School of Medicine have developed an equation to measure the volume of the placenta, providing a reliable way to monitor fetal growth and prevent pregnancy loss. The 'Estimated Placenta Volume' (EPV) test has shown accuracy of up to 89%, with potential to become routine for pregnant women.